Curanex Pharmaceuticals Inc
CURX
$0.32
-$0.01-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.98M | 677.50K | -- | -- | -- |
| Gross Profit | -2.98M | -677.50K | -- | -- | -- |
| SG&A Expenses | 1.26M | 541.80K | 361.20K | 347.70K | 290.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.24M | 1.22M | 361.20K | 347.70K | 290.40K |
| Operating Income | -4.24M | -1.22M | -361.20K | -347.70K | -290.40K |
| Income Before Tax | -4.23M | -1.30M | -435.00K | -418.90K | -361.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.23 | -1.30 | -0.44 | -0.42 | -0.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.23M | -1.30M | -435.00K | -418.90K | -361.50K |
| EBIT | -4.24M | -1.22M | -361.20K | -347.70K | -290.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.15 | -0.05 | -0.05 | -0.07 | -0.19 |
| Normalized Basic EPS | -0.10 | -0.03 | -0.03 | -0.04 | -0.12 |
| EPS Diluted | -0.15 | -0.05 | -0.05 | -0.07 | -0.19 |
| Normalized Diluted EPS | -0.10 | -0.03 | -0.03 | -0.04 | -0.12 |
| Average Basic Shares Outstanding | 101.97M | 114.04M | 90.84M | 69.24M | 45.84M |
| Average Diluted Shares Outstanding | 101.97M | 114.04M | 90.84M | 69.24M | 45.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |